Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pseudomonas Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF

NCT01303068
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
13C urea breath test Kit
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00104520
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 4 Interventional Results available

The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas

NCT03158116
View directory record Official record
Conditions
Tracheostomy Infection
Interventions
Inhaled Aztreonam
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
7 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 17, 2026, 5:16 AM EDT
Not listed Phase 1 Interventional

IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma

NCT00003842
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
Biological · Drug · Procedure
Lead sponsor
Barrett Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma

NCT01445392
View directory record Official record
Conditions
Mesothelioma
Interventions
Multicycle SS1P, Pemetrexed, Cisplatin, Single cycle SS1P
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

NCT04145531
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
Interventions
IM JZP-458, IV JZP-458
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Approved For Marketing No phase listed Expanded access

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

NCT00499720
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Interventions
Aztreonam Lysine for Inhalation
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
U.S. locations
64
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2011 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 4 Interventional

Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

NCT00481689
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Cipro XR (Ciprofloxacin, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2009 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

NCT01051934
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Adenocarcinoma
Interventions
SS1 (dsFv) PE38, Paclitaxel, Carboplatin, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

NCT01515007
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Peoria, Arizona • Phoenix, Arizona • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 17, 2026, 5:16 AM EDT
Completed No phase listed Observational

Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa

NCT00027183
View directory record Official record
Conditions
Pseudomonas Infection, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
9 Years to 99 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Sentinel Cohort REACT

NCT05780801
View directory record Official record
Conditions
Multi-Drug Resistant Organism
Interventions
Allogeneic Microbiota in Glycerol (10%) (AMG)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Sep 17, 2026, 5:16 AM EDT
Completed No phase listed Observational

Tissue Collection From People With Cystic Fibrosis

NCT00015756
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
9 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

NCT00712166
View directory record Official record
Conditions
Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
Interventions
AZLI 75 mg three times daily (TID), Placebo three times daily (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2010 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

NCT05010577
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
Interventions
BX004-A, Placebo
Drug
Lead sponsor
BiomX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)

NCT04684641
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Standard Dose YPT-01, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

NCT06159725
View directory record Official record
Conditions
Persistent Infection, Cystic Fibrosis
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Phase 2 Interventional

PMT for MDRO Decolonization

NCT05632315
View directory record Official record
Conditions
Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, Pseudomonas Aeruginosa, VRE Infection, Methicillin-resistant Staphylococcus Aureus
Interventions
PMT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed No phase listed Observational

Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

NCT03510351
View directory record Official record
Conditions
Pseudomonas Infections, Pseudomonas Aeruginosa
Interventions
Ceftolozane-Tazobactam
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases

NCT00003020
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
LMB-7 immunotoxin
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)

NCT00128492
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 3 Interventional

Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

NCT03582007
View directory record Official record
Conditions
Pneumonia
Interventions
Murepavadin, One anti-pseudomonal antibiotic
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 17, 2026, 5:16 AM EDT